HCC: Key topics discussed at ASCO GI & EASL 2022

December 06, 2023 • 00:13:11
HCC: Key topics discussed at ASCO GI & EASL 2022
COR2ED - Oncology Medical Conversation
HCC: Key topics discussed at ASCO GI & EASL 2022

Dec 06 2023 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode

December 06, 2023 • 00:22:19
Episode Cover

Colorectal cancer: Flexible dosing of oral treatments in mCRC

In this podcast, Sven De Keersmaecker, RN and Assoc. Prof. Gerald Prager, MD discuss flexible dosing regimens of the oral treatments regorafenib, trifluridine /...

Listen

Episode

March 31, 2025 • 00:13:43
Episode Cover

ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses

In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase...

Listen

Episode

March 28, 2024 • 00:26:15
Episode Cover

Perseverance pays off – Looking beyond the obvious mutations in NSCLC

Why is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are...

Listen